Tura, A.* ; Grespan, E.* ; Göbl, C.S.* ; Koivula, R.W.* ; Franks, P.W.* ; Pearson, E.R.* ; Walker, M.* ; Forgie, I.M.* ; Giordano, G.N.* ; Pavo, I.* ; Ruetten, H.* ; Dermitzakis, E.T.* ; McCarthy, M.I.* ; Pedersen, O.* ; Schwenk, J.M.* ; Adamski, J. ; De Masi, F.* ; Tsirigos, K.D.* ; Brunak, S.* ; Viñuela, A.* ; Mahajan, A.* ; McDonald, T.J.* ; Kokkola, T.* ; Vangipurapu, J.* ; Cederberg, H.* ; Laakso, M.* ; Rutters, F.* ; Elders, P.J.M.* ; Koopman, A.D.M.* ; Beulens, J.W.* ; Ridderstråle, M.* ; Hansen, T.H.* ; Allin, K.H.* ; Hansen, T.* ; Vestergaard, H.* ; Mari, A.* ; IMI DIRECT Consortium (Grallert, H. ; Sharma, S. ; Thorand, B.)
Profiles of glucose metabolism in different prediabetes phenotypes, classified by fasting glycemia, 2-hour OGTT, glycated hemoglobin, and 1-hour OGTT: An IMI DIRECT study.
Diabetes 70, 2092-2106 (2021)
Differences in glucose metabolism among categories of prediabetes have not been systematically investigated. In this longitudinal study, participants (N=2111) underwent 2h-75g OGTT at baseline and 48 months. HbA1c was also measured. We classified participants as having isolated prediabetes defect (impaired fasting glucose, IFG; impaired glucose tolerance, IGT; HbA1c-prediabetes, IA1c), two defects (IFG+IGT, IFG+IA1c, IGT+IA1c), or all defects (IFG+IGT+IA1c). Beta-cell function (BCF) and insulin sensitivity (IS) were assessed from OGTT. At baseline, when pooling participants with isolated defects, they showed impairment in both BCF and IS compared to healthy controls. Pooled groups with two or three defects showed progressive further deterioration. Among groups with isolated defect, IGT showed lower IS, insulin secretion at reference glucose (ISRr), and insulin secretion potentiation (p<0.002). Conversely, IA1c showed higher IS and ISRr (p<0.0001). Among groups with two defects, we similarly found differences in both BCF and IS. At 48 months, we found higher type 2 diabetes incidence for progressively increasing number of prediabetes defects (odds ratio >2, p<0.008). In conclusion, the prediabetes groups showed differences in type/degree of glucometabolic impairment. Compared to the pooled group with isolated defects, those with double or triple defect showed progressive differences in diabetes incidence.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Beta-cell Dysfunction; Cardiovascular Risk Profile; Insulin-resistance; Plasma-glucose; Identify Subjects; Tolerance; Individuals; Hyperglycemia; Sensitivity; Regression
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2021
Prepublished im Jahr
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
0012-1797
e-ISSN
1939-327X
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 70,
Heft: 9,
Seiten: 2092-2106
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
American Diabetes Association
Verlagsort
Alexandria, VA.
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30201 - Metabolic Health
30202 - Environmental Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-500600-001
G-504091-002
G-504000-002
Förderungen
Pfizer
Servier
Sanofi
Novo Nordisk A/S
Eli Lilly
Boehringer Ingelheim
Novo Nordisk Foundation postdoctoral fellowship
STAR Award Novo Nordisk
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Union's Seventh Framework Programme
Merck
Janssen
Takeda
Roche
AstraZeneca
AbbVie
National Institute for Health Research (NIHR)
Wellcome Investigator
Innovative Medicines Initiative Joint Undertaking
Copyright
Erfassungsdatum
2021-08-02